Cost and utility value parameters
| Variable | Median | Range | Distribution | Source | |
| Costs | Lower limit | Higher limit | |||
| FTD/TPI (per cycle) | US$2112.50 | US$1901.25 | US$2323.75 | Gamma | (14) |
| Adverse events cost (TAGS) | US$3485.00 | US$3136.50 | US$3833.5 | Gamma | (15–20)(22) |
| Neutropenia (34%) (per cycle) | US$3448.75 | US$3103.88 | US$3793.63 | Gamma | (15–20)(22) |
| Anaemia (19%) (per cycle) | US$24.62 | US$22.16 | US$27.08 | Gamma | (15–20)(22) |
| Leucopenia (9%) (per cycle) | US$11.62 | US$10.64 | US$12.78 | Gamma | (15–20)(22) |
| Adverse events cost (placebo) | US$27.33 | US$24.60 | US$30.06 | Gamma | (15–20)(22) |
| Bellyache (9%) (per cycle) | US$2.71 | US$2.44 | US$2.98 | Gamma | (15–20)(22) |
|
Anaemia (8%) (per cycle) | US$24.62 | US$22.16 | US$27.08 | Gamma | (15–20)(22) |
|
Imaging cost (per cycle) | US$304.55 | US$274.1 | US$335.01 | Gamma | (15–20) |
|
Administration cost (per cycle) | US$353.22 | US$317.9 | US$388.54 | Gamma | (15–20)(22) |
|
Best supportive care cost (per cycle) | US$1127.97 | US$1015.17 | US$1240.77 | Gamma | (15–20)(21) |
| Utilities | |||||
| Progression-free survival | 0.764 | 0.688 | 0.841 | Beta | (19) |
| Progressed disease | 0.652 | 0.587 | 0.717 | Beta | (19) |
| Death | 0 | 0 | 0 | Beta | (19) |
FTD/TPI, trifluridine/tipiracil.